HNHuyen Thi Lam Nguyen

Huyen Thi Lam Nguyen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huyen Thi Lam Nguyen has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Ahmad Al Shihabi

    Department of Pathology, David Geffen School of Medicine, University of California Los Angeles

    1 shared publication
  • Alice Soragni

    Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

    1 shared publication
  • Ardalan Davarifar

    The University of Tennessee Medical Center, Knoxville, USA

    1 shared publication
  • Francis Hornicek

    Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

    1 shared publication
  • Jane Yanagawa

    Division of Thoracic Surgery, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

    1 shared publication
  • Nasrin Tavanaie

    Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    Personalized chordoma organoids for drug discovery studies

    by Ahmad Al Shihabi, Ardalan Davarifar, Huyen Thi Lam Nguyen, Nasrin Tavanaie, Scott D. Nelson, Jane Yanagawa, Noah Federman, Nicholas Bernthal, Francis Hornicek, Alice Soragni

    Chordomas are rare tumors of notochordal origin, most commonly arising in the sacrum or skull base. Chordomas are considered insensitive to conventional chemotherapy, and their rarity complicates running timely and adequately powered trials to identify effective treatments. Therefore, there is a need for discovery of novel therapeutic approaches. Patient-derived organoids can accelerate drug discovery and development studies and predict patient responses to therapy. In this proof-of-concept study, we successfully established organoids from seven chordoma tumor samples obtained from five patients presenting with tumors in different sites and stages of disease. The organoids recapitulated features of the original parent tumors and inter- as well as intrapatient heterogeneity. High-throughput screenings performed on the organoids highlighted targeted agents such as PI3K/mTOR, EGFR, and JAK2/STAT3 inhibitors among the most effective molecules. Pathway analysis underscored how the NF-κB and IGF-1R pathways are sensitive to perturbations and potential targets to pursue for combination therapy of chordoma.